Patterns of pregnancy exposure to prescription FDA C, D and X drugs in a Canadian population

Journal of Perinatology

Volumn 28, Issue 5, 2008, Pages 324-329

  Wen, S W ^a,b,c   Yang, T ^a,b,c   Krewski, D ^a,d   Yang, Q ^a,b   Nimrod, C ^g   Garner, P ^g   Fraser, W ^e   Olatunbosun, O ^f   Walker, M C ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c CENTRAL SOUTH UNIVERSITY   (China)

^d RISK SCIENCES INTERNATIONAL   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f UNIVERSITY OF SASKATCHEWAN   (Canada)

^g NONE

Author keywords

Antibiotics; Antidepressants; FDA pregnancy risk classifi cation; Oral contraceptives; Pregnancy; Prescription drug

Indexed keywords

AMITRIPTYLINE; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BECLOMETASONE; CODEINE; COTRIMOXAZOLE; DIAZEPAM; DOXYCYCLINE; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS NORGESTREL; FLUCONAZOLE; FLUTICASONE; HYDROXYZINE; IBUPROFEN; INDOMETACIN; LORAZEPAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; NORGESTREL; NYSTATIN; ORAL CONTRACEPTIVE AGENT; PARACETAMOL; PAROXETINE; PETHIDINE; PROPYLTHIOURACIL; SALBUTAMOL; TETRACYCLINE; UNINDEXED DRUG;

ADULT; ARTICLE; CANADA; COHORT ANALYSIS; DRUG CLASSIFICATION; FEMALE; FIRST TRIMESTER PREGNANCY; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; PRENATAL DRUG EXPOSURE; PRESCRIPTION; RISK ASSESSMENT; SECOND TRIMESTER PREGNANCY; THIRD TRIMESTER PREGNANCY;

ADULT; ALBUTEROL; CONTRACEPTIVES, ORAL; CROSS-SECTIONAL STUDIES; DRUG TOXICITY; FEMALE; GESTATIONAL AGE; HUMANS; IBUPROFEN; INFANT, NEWBORN; NAPROXEN; PHARMACEUTICAL PREPARATIONS; POPULATION SURVEILLANCE; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; PRESCRIPTIONS, DRUG; SASKATCHEWAN; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 43049088474     PISSN: 07438346     EISSN: 14765543     Source Type: Journal    
DOI: 10.1038/jp.2008.6     Document Type: Article

References (27)

1. Rajkumar SV. Thalidomide: Tragic past and proming future. Mayo Clin Proc 2004; 79: 899-903.
2. Lagoy CT, Joshi N, Cragan JD, Rasmussen SA. Ose during pregnancy and lactation: An urgent call for public health action. J Womens Health 2005; 14: 104-109.
3. Food and Drug Administration. Requirements on content and forms of labeling for human prescription drug and biological products. Fed Regist 2006; 71: 3921-3997,
4. Wen SW, Yang Q, Garner P, Fraser W, Olatunbosun O, Nimrod C et al. Selective serotonin reuptake inhibitors and adverse pregnancy outcomes. Am J Obstet Gynecol 2006; 194: 961-966.
5. Von Korff M, Wagner EH, Saunders K. A chronic disease score from automated pharmacy data. J Clin Epidemiol 1992; 45: 197-203.
6. Lee E, Maneno MK, Smith L, Weiss SR, Zuckerman IH, Wutoh AK et al. National patterns of medication use during pregnancy. Pharmacoepidemiol Drug Saf 2006; 15: 537-545.
7. Andrade SE, Gurwitz JH, Davis RL, Chan KA, Finkelstein JA, Fortman K et al. Prescription drug use in pregnancy. Am J Obstet Gynecol 2004; 191: 398-407.
8. Andrade SE, Raebel MA, Morse AN, Davis RL, Chan KA, Finkelstein JA et al. Use of prescription medications with a potential for fetal harm among pregnant women. Pharmacoepidemiol Drug Saf 2006; 15: 546-554.
9. Cooper WO, Hickson GB, Ray WA. Prescriptions for contraindicated category X drugs in pregnancy among women enrolled in TennCare. Paediatr Perinat Epidemiol 2004; 18: 106-111.
10. Malm H, Martikainen J, Klaukka T, Neuvonen P. Prescription of hazardous drugs during pregnancy. Drug Saf 2004; 27: 899-908.
11. Lacroix I, Damase-Michel C, Lapeyre-Mestre M, Montastruc JL. Prescription of drugs during pregnancy in France. Lancet 2000; 356: 1735-1736.
12. Bakker MK, Jentink J, Vroom F, Van Den Berg PB, De Walle BE, De Jong-Van Den Berg LT. Drug prescription patterns before, during and after pregnancy for chronic, occasional and pregnancy-related drugs in the Netherlands. BJOG 2006; 113: 559-568.
13. Riley EH, Fuentes-Afflick E, Jackson RA, Escobar GJ, Brawarsky P, Schreiber M et al. Correlates of prescription drug use during pregnancy. J Womens Health 2005; 14: 401-409.
14. Hardy JR, Leaderer BP, Holford TR, Hall GC, Bracken MB. Safety of medications prescribed before and during early pregnancy in a cohort of 81975 mothers from the UK General Practice Research Database. Pharmacoepidemiol Drug Saf 2006; 15: 555-564.
15. Olesen C, Sprensen HT, de Jong-van-den Berg L, Olsen J, Steffensen FH. Prescribing during pregnancy and lactation with reference to the Swedish classification system. A population-based study among Danish women. The GuromaysEuromap Group. Acta Obstet Gynecol Scand 1999; 78: 686-692.
16. Garriguet D. Medication use among pregnant women. Health Rep 2006; 17: 9-18.
17. Williams JI, Young W. A summary on the quality of health care administrative databases in Canada. In: Goel V, Williams JI, Anderson GM, Blackstien-Hirsch P, Fooks C, Naylor CD (eds). Patterns of Health Care in Ontario. The ICES Practice Atlas, 2nd edn. Canadian Medical Association: Ottawa, 1996.
18. Schieve LA, Handler A, Hershow R, Persky V, Davis F. Urinary tract infection during pregnancy: Its association with maternal morbidity and perinatal outcome. Am J Public Health 1994; 84: 405-410.
19. Masters PA, O'Bryan TA, Zurlo J, Miller D, Joshi N. Trimethoprim-sulfamethoxazole revisited. Arch Intern Med 2003; 163: 402-410.
20. Wen SW, Walker M. Risk of fetal exposure to folic acid antagonists. J Obstet Gynaecol Can 2004; 26: 475-480.
21. Hernández-Díaz S, Werler MM, Walker AM, Mitchell AA. Fofic acid antagonists during pregnancy and the risk of birth defects. N Engl J Med 2000; 343: 1608-1614.
22. Wen SW, Demissie KW, Liu S. Adverse outcomes in pregnancies of asthmatic women: Results from a Canadian population, Ann Epidemiol 2001; 11: 7-12.
23. Demissie K, Breckenridge MB, Rhoads GG. Infant and maternal outcomes in the pregnancies of asthmatic women. Am J Respir Crit Care Med 1998; 158: 1091-1095.
24. Källén B, Otterblad Olausson P. Use of anti-asthmatic drugs during pregnancy 3. Congenital malformations in the infants. Eur J Clin Pharmacol 2007; 63: 383-388.
25. Henshaw SK. Unintended pregnancy in the United States. Fam Plan Perspect 1998; 30: 24-29, 46.
26. Foster DG, Bley J, Mikanda J, Induni M, Arons A, Baumrind N et al. Contraceptive use and risk of unintended pregnancy in California. Contraception 2004; 70: 31-39.
27. Glei DA. Measuring contraceptive use patterns among teenage and adult women. Fam Plan Perspect 1999; 31: 73-80.